

Antonella Ferro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9148894/publications.pdf>

Version: 2024-02-01

49
papers

2,817
citations

331538

21
h-index

214721

47
g-index

53
all docs

53
docs citations

53
times ranked

4437
citing authors

#	ARTICLE	IF	CITATIONS
1	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012, 379, 633-640.	6.3	1,165
2	Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the <i>PIK3CA</i> Gene in Breast Carcinomas. <i>Clinical Cancer Research</i> , 2007, 13, 6064-6069.	3.2	186
3	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	0.8	182
4	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 ² factorial, randomised phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1863-1872.	6.3	164
5	Pain and Quality of Life after Surgery for Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 80, 39-48.	1.1	146
6	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. <i>Annals of Oncology</i> , 2018, 29, 2328-2333.	0.6	124
7	Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. <i>Diagnostic Pathology</i> , 2011, 6, S7.	0.9	83
8	UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. <i>Oncogene</i> , 2007, 26, 2136-2140.	2.6	68
9	Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. <i>Annals of Oncology</i> , 2019, 30, 418-423.	0.6	66
10	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 474-485.	5.1	59
11	Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors. <i>Urology</i> , 2012, 79, 644-649.	0.5	50
12	Angiogenesis and antiangiogenic agents in non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 34, 3-7.	0.9	48
13	Integrating mHealth in Oncology: Experience in the Province of Trento. <i>Journal of Medical Internet Research</i> , 2015, 17, e114.	2.1	46
14	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. <i>Breast</i> , 2013, 22, 1060-1065.	0.9	33
15	Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. <i>Annals of Oncology</i> , 2003, 14, 843-848.	0.6	27
16	PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 129-139.	1.4	26
17	9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.. <i>Journal of Clinical Oncology</i> , 2017, 35, 501-501.	0.8	26
18	Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience. <i>Annals of Oncology</i> , 2009, 20, 349-352.	0.6	23

#	ARTICLE	IF	CITATIONS
19	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 147-154.	1.1	23
20	<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2989-2997.	1.0	23
21	In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 45-50.	1.4	22
22	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. <i>BMC Cancer</i> , 2006, 6, 202.	1.1	21
23	CDC25A Protein Stability Represents a Previously Unrecognized Target of HER2 Signaling in Human Breast Cancer: Implication for a Potential Clinical Relevance in Trastuzumab Treatment. <i>Neoplasia</i> , 2013, 15, 579-590.	2.3	18
24	Pharmacogenetic interaction analysis of <i>VEGFR-2</i> and <i>IL-8</i> polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. <i>Pharmacogenomics</i> , 2014, 15, 1985-1999.	0.6	16
25	Diagnostic Value of Automated Her2 Evaluation in Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 306-312.	0.6	15
26	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016, 7, 72654-72661.	0.8	15
27	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 479-488.	1.1	14
28	The use of breast imaging for predicting response toÂneoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: ResultsÂfrom Neo-ALTT0. <i>European Journal of Cancer</i> , 2018, 89, 42-48.	1.3	13
29	PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 85-93.	1.4	12
30	Implementation and evaluation of an Asbru-based decision support system for adjuvant treatment in breast cancer. <i>Computer Methods and Programs in Biomedicine</i> , 2014, 117, 308-321.	2.6	12
31	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pNO Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0136731.	1.1	11
32	Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients. <i>Future Oncology</i> , 2015, 11, 1493-1500.	1.1	10
33	Electronic Medical RecordÂAssisted Telephone Follow-Up of Breast Cancer Survivors During the COVID-19 Pandemic: A Single Institution Experience. <i>JCO Oncology Practice</i> , 2021, 17, e44-e52.	1.4	10
34	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019, 154, 83-88.	0.6	9
35	Modeling Clinical Protocols Using Semantic MediaWiki: The Case of the Oncocure Project. <i>Lecture Notes in Computer Science</i> , 2009, , 42-54.	1.0	8
36	Exploring metastatic breast cancer treatment changes during COVID-19 pandemic. <i>Journal of Chemotherapy</i> , 2021, 33, 263-268.	0.7	7

#	ARTICLE	IF	CITATIONS
37	An ontology of cancer therapies supporting interoperability and data consistency in EPRs. <i>Computers in Biology and Medicine</i> , 2013, 43, 822-832.	3.9	6
38	Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 953-957.	1.2	5
39	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , 2019, 17, 207.	2.3	4
40	Bridging an Asbru Protocol to an Existing Electronic Patient Record. <i>Lecture Notes in Computer Science</i> , 2010, , 14-25.	1.0	4
41	Embedding oncologic protocols into the provision of care: the Oncocure project. <i>Studies in Health Technology and Informatics</i> , 2009, 150, 663-7.	0.2	3
42	A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients. <i>Npj Breast Cancer</i> , 2022, 8, 33.	2.3	3
43	Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 654-659.	0.7	2
44	Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer. <i>Annals of Oncology</i> , 2017, 28, vi1.	0.6	2
45	Learning from organisational changes in the management of breast cancer patients during the COVID-19 pandemic: Preparing for a second wave at a breast unit in northern Italy. <i>International Journal of Health Planning and Management</i> , 2021, 36, 1030-1037.	0.7	2
46	Management of Breast Cancer Patients during the COVID-19 Pandemic in Northern Italy. <i>Breast Care</i> , 2021, 16, 418-421.	0.8	0
47	Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21102-e21102.	0.8	0
48	Neoadjuvant chemotherapy (NC) in invasive breast cancer (IBC) subtypes: Outcomes according to pathological complete response (pCR) and proliferation index (PI) of residual tumor (RT).. <i>Journal of Clinical Oncology</i> , 2015, 33, e12027-e12027.	0.8	0
49	Abstract P2-16-24: Impact of pathologic complete response (pCR) and biological features of residual tumor (RT) on prognosis after neoadjuvant chemotherapy (NC) in various invasive breast cancer (IBC) subtypes. , 2020, , .		0